Investigation of Individualised Antisense Oligonucleotides (ASOs) in People With Unique Genetic Variants Causing Severely Debilitating, Life Threatening (SDLT) Central Nervous System (CNS) Conditions

计划入组 1 人 · 首次发布于 2026 年 2 月 13 日

Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy

计划入组 7 人 · 首次发布于 2005 年 9 月 12 日

Safety and Pharmacokinetics of IMT504, an Immunomodulator and Tissue Repair Inducer

计划入组 12 人 · 首次发布于 2024 年 3 月 15 日

antisense oligonucleotides (Pfizer)

Antisense oligonucleotides

Antisense oligonucleotides (Ionis)

Antisense Therapeutics Ltd

PERCHERON THERAPEUTICS LIMITED

Australia

Ionis Pharmaceuticals, Inc.

United States

Antisense Oligonucleotides: Rewriting the Future of Rare Inherited Genetic Diseases

AcuraStem Awarded $4 Million CIRM Grant to Advance UNC13A-Targeted Therapy for ALS and FTD

Advancing Personalized Medicine: The Rise of N-of-1 Therapies for Rare Diseases